These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 26956052)

  • 1. Survival kinase genes present prognostic significance in glioblastoma.
    Varghese RT; Liang Y; Guan T; Franck CT; Kelly DF; Sheng Z
    Oncotarget; 2016 Apr; 7(15):20140-51. PubMed ID: 26956052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PIK3CB/p110β is a selective survival factor for glioblastoma.
    Pridham KJ; Le L; Guo S; Varghese RT; Algino S; Liang Y; Fajardin R; Rodgers CM; Simonds GR; Kelly DF; Sheng Z
    Neuro Oncol; 2018 Mar; 20(4):494-505. PubMed ID: 29016844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
    Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
    Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
    Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC
    Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A DNA Repair and Cell-Cycle Gene Expression Signature in Primary and Recurrent Glioblastoma: Prognostic Value and Clinical Implications.
    Gobin M; Nazarov PV; Warta R; Timmer M; Reifenberger G; Felsberg J; Vallar L; Chalmers AJ; Herold-Mende CC; Goldbrunner R; Niclou SP; Van Dyck E
    Cancer Res; 2019 Mar; 79(6):1226-1238. PubMed ID: 30674534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clonal evolution of glioblastoma under therapy.
    Wang J; Cazzato E; Ladewig E; Frattini V; Rosenbloom DI; Zairis S; Abate F; Liu Z; Elliott O; Shin YJ; Lee JK; Lee IH; Park WY; Eoli M; Blumberg AJ; Lasorella A; Nam DH; Finocchiaro G; Iavarone A; Rabadan R
    Nat Genet; 2016 Jul; 48(7):768-76. PubMed ID: 27270107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
    Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
    Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma.
    Furuta T; Sabit H; Dong Y; Miyashita K; Kinoshita M; Uchiyama N; Hayashi Y; Hayashi Y; Minamoto T; Nakada M
    Oncotarget; 2017 Apr; 8(14):22811-22824. PubMed ID: 28423558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MPC1 deletion is associated with poor prognosis and temozolomide resistance in glioblastoma.
    Chai Y; Wang C; Liu W; Fan Y; Zhang Y
    J Neurooncol; 2019 Sep; 144(2):293-301. PubMed ID: 31236818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme.
    Han J; Puri RK
    J Neurooncol; 2018 Feb; 136(3):463-474. PubMed ID: 29168083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NAMPT: A potential prognostic and therapeutic biomarker in patients with glioblastoma.
    Guo Q; Han N; Shi L; Yang L; Zhang X; Zhou Y; Yu S; Zhang M
    Oncol Rep; 2019 Sep; 42(3):963-972. PubMed ID: 31322259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 expression and prognostic impact in glioblastoma.
    Nduom EK; Wei J; Yaghi NK; Huang N; Kong LY; Gabrusiewicz K; Ling X; Zhou S; Ivan C; Chen JQ; Burks JK; Fuller GN; Calin GA; Conrad CA; Creasy C; Ritthipichai K; Radvanyi L; Heimberger AB
    Neuro Oncol; 2016 Feb; 18(2):195-205. PubMed ID: 26323609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cotargeting Ephrin Receptor Tyrosine Kinases A2 and A3 in Cancer Stem Cells Reduces Growth of Recurrent Glioblastoma.
    Qazi MA; Vora P; Venugopal C; Adams J; Singh M; Hu A; Gorelik M; Subapanditha MK; Savage N; Yang J; Chokshi C; London M; Gont A; Bobrowski D; Grinshtein N; Brown KR; Murty NK; Nilvebrant J; Kaplan D; Moffat J; Sidhu S; Singh SK
    Cancer Res; 2018 Sep; 78(17):5023-5037. PubMed ID: 29945963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients.
    Yong WH; Shabihkhani M; Telesca D; Yang S; Tso JL; Menjivar JC; Wei B; Lucey GM; Mareninov S; Chen Z; Liau LM; Lai A; Nelson SF; Cloughesy TF; Tso CL
    PLoS One; 2015; 10(10):e0141334. PubMed ID: 26506620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 63 signature genes prediction system is effective for glioblastoma prognosis.
    Zhang Y; Xu J; Zhu X
    Int J Mol Med; 2018 Apr; 41(4):2070-2078. PubMed ID: 29393370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials.
    Ellingson BM; Harris RJ; Woodworth DC; Leu K; Zaw O; Mason WP; Sahebjam S; Abrey LE; Aftab DT; Schwab GM; Hessel C; Lai A; Nghiemphu PL; Pope WB; Wen PY; Cloughesy TF
    Neuro Oncol; 2017 Jan; 19(1):89-98. PubMed ID: 27580889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction of co-expression modules related to survival by WGCNA and identification of potential prognostic biomarkers in glioblastoma.
    Zhou J; Guo H; Liu L; Hao S; Guo Z; Zhang F; Gao Y; Wang Z; Zhang W
    J Cell Mol Med; 2021 Feb; 25(3):1633-1644. PubMed ID: 33449451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated microenvironment-associated genomic profiles identify LRRC15 mediating recurrent glioblastoma-associated macrophages infiltration.
    Tang H; Liu W; Xu Z; Zhao J; Wang W; Yu Z; Wei M
    J Cell Mol Med; 2021 Jun; 25(12):5534-5546. PubMed ID: 33960636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel gene signature based on five glioblastoma stem-like cell relevant genes predicts the survival of primary glioblastoma.
    Chai R; Zhang K; Wang K; Li G; Huang R; Zhao Z; Liu Y; Chen J
    J Cancer Res Clin Oncol; 2018 Mar; 144(3):439-447. PubMed ID: 29299749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A DNA methylation prognostic signature of glioblastoma: identification of NPTX2-PTEN-NF-κB nexus.
    Shukla S; Pia Patric IR; Thinagararjan S; Srinivasan S; Mondal B; Hegde AS; Chandramouli BA; Santosh V; Arivazhagan A; Somasundaram K
    Cancer Res; 2013 Nov; 73(22):6563-73. PubMed ID: 24078801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.